Abivax
Coverage of Abivax in the Nexus archive.
- Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBC
Abivax secured $920 million in funding, enabling the French biotech company to prepare for an independent U.S. launch without relying on a buyer. The funds will cover operations through 2029.
- Abivax stock surges as new trial data ease cancer fears over bowel disease drug
Abivax stock surged following new Phase 3 trial data indicating malignancy rates among ulcerative colitis patients align with typical expectations, easing concerns about cancer risks linked to the bowel disease drug.
- French biotech stock soars 31% after new data on experimental medicine
Shares of French biotech company Abivax rose 31% after releasing new data on its lead drug for bowel disease.
- STAT+: Abivax seeks to ease safety concerns with new data, boosting shares
Abivax released additional data on its experimental ulcerative colitis drug obefazimod to address safety concerns, leading to a 25% rise in U.S.-listed shares. The drug showed strong efficacy in a maintenance trial, but prior cancer cases among participants had raised safety risks.
- STAT+: Radiopharmaceutical shows promise in post-Pluvicto setting
A radiopharmaceutical shows promise in the post-Pluvicto setting. Vera Therapeutics and the FDA agreed to accelerate analysis of a Phase 3 study for atacicept in treating IgA nephropathy, while Abivax reported positive data for an ulcerative colitis treatment despite cancer concerns.
- Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
Shares of French biotech Abivax fell 32% following updated trial data on its lead asset for bowel disease. The stock decline occurred after the company reported fresh data on its primary drug candidate.
- STAT+: Abivax ulcerative colitis drug shows strong efficacy, but cases of cancer raise concerns
Abivax's experimental drug obefazimod showed strong efficacy in a Phase 3 trial for ulcerative colitis, with over 50% of participants achieving clinical remission. However, the company's shares dropped after reporting cancer cases among treated patients, raising safety concerns.